Bristol-Myers Competitors

Summary

Bristol-Myers Squibb competes with US Silica, Western Digital, US GoldMining, Analog Devices, and Marti Technologies; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers - Major industry. Analyzing Bristol-Myers Squibb competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bristol-Myers Squibb to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bristol-Myers Squibb competition on your existing holdings.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bristol-Myers Squibb's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bristol-Myers Squibb in the context of predictive analytics.

Hype

Prediction

Low	Estimated	High
0.00	0.00	0.00

Details

Intrinsic

Valuation

Low	Real	High
0.00	0.00	0.00

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bristol-Myers Squibb. Your research has to be compared to or analyzed against Bristol-Myers Squibb's peers to derive any actionable benefits. When done correctly, Bristol-Myers Squibb's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Bristol-Myers Squibb.

Bristol-Myers Squibb Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bristol-Myers Squibb and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Bristol-Myers and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bristol-Myers Squibb does not affect the price movement of the other competitor.

	SLCA	WDC	USGO	ADI	MRT	NB	MBIO
SLCA		-0.22	0.57	-0.06	0.53	0.02	0.58	SLCA
WDC	-0.22		0.28	0.77	0.4	-0.76	-0.07	WDC
USGO	0.57	0.28		0.55	0.9	-0.49	0.79	USGO
ADI	-0.06	0.77	0.55		0.58	-0.69	0.34	ADI
MRT	0.53	0.4	0.9	0.58		-0.53	0.69	MRT
NB	0.02	-0.76	-0.49	-0.69	-0.53		-0.1	NB
MBIO	0.58	-0.07	0.79	0.34	0.69	-0.1		MBIO
	SLCA	WDC	USGO	ADI	MRT	NB	MBIO

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

MRT	+ 0.9	USGO
MBIO	+ 0.79	USGO
ADI	+ 0.77	WDC
MBIO	+ 0.69	MRT
MBIO	+ 0.58	SLCA
MRT	+ 0.58	ADI

High negative correlations

NB	- 0.76	WDC
NB	- 0.69	ADI
NB	- 0.53	MRT
NB	- 0.49	USGO
WDC	- 0.22	SLCA
MBIO	- 0.1	NB

Risk-Adjusted Indicators

There is a big difference between Bristol-Myers Pink Sheet performing well and Bristol-Myers Squibb company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bristol-Myers Squibb's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Information Ratio	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
SLCA	1.67	(0.15)	0.00	(0.11)	0.00	(0.06)	0.00	4.29	(3.43)	12.65
WDC	1.65	0.21	0.08	0.26	2.34	0.09	(1.64)	3.94	(3.52)	15.13
USGO	3.36	(0.38)	0.00	(0.43)	0.00	(0.08)	0.00	8.48	(7.64)	22.93
ADI	1.07	0.01	0.01	0.02	1.27	0.0112	(1.14)	2.18	(2.05)	5.46
MRT	3.62	(0.02)	0.00	0.00	3.77	(0.0009)	(5.45)	10.26	(7.41)	18.71
NB	3.54	(0.11)	0.00	0.13	0.00	(0.0255)	0.00	7.08	(8.15)	28.70
MBIO	3.47	(1.19)	0.00	(0.73)	0.00	(0.27)	0.00	4.70	(7.05)	21.26

Bristol-Myers Squibb Competitive Analysis

The better you understand Bristol-Myers Squibb competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bristol-Myers Squibb's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bristol-Myers Squibb's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	SLCA	WDC	USGO	ADI	MRT	NB	MBIO
	0.71 11.36 SLCA	0.17 48.39 Western	3.92 7.35 USGO	0.30 183.07 Analog	12.31 0.73 Marti	0.62 3.23 NioCorp	1.41 1.44 Mustang
Market Volatility (90 Days Market Risk)	Not too volatile	Very steady	Slightly risky	Very steady	Extremely Dangerous	Relatively risky	Moderately volatile
Market Performance (90 Days Performance)	Very Weak	Insignificant	Very Weak	Weak	Very Weak	Very Weak	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Very Small	Below Average	Average	Very Small	Average	Low	High
Current Valuation (Equity Enterprise Value)	Under Valued	Fairly Valued	Under Valued	Fairly Valued	Under Valued	Under Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Hold	Buy	Buy	Buy	Hold	Strong Buy	Strong Buy
Trade Advice (90 Days Macroaxis Advice)	Strong Buy	Strong Buy	Strong Hold	Strong Buy	Cautious Hold	Strong Sell	Strong Hold
Current Ratio	2.76 X	1.83 X	N/A	2.02 X	0.17 X	N/A	9.96 X
Net Asset	2.21 B	24.43 B	229.62 K	48.79 B	149.07 M	20.93 M	92.42 M
Profit Margin	0.09 %	(0.21) %	N/A	0.27 %	N/A	N/A	N/A
EBITDA	321.76 M	(264 M)	(1.71 M)	6.33 B	(837.12 K)	(37.41 M)	(74.17 M)
Operating Margin	0.17 %	0.15 %	N/A	0.27 %	N/A	N/A	N/A
Current Valuation	1.61 B	20.84 B	55.63 M	96.92 B	N/A	151.75 M	5.64 M
Price To Book	1.06 X	1.50 X	N/A	2.55 X	N/A	N/A	3.15 X
Retained Earnings	(351.08 M)	7.42 B	(5.12 M)	10.36 B	(4.99 M)	(150.48 M)	(329.37 M)
Current Asset	439.14 M	12.58 B	N/A	4.97 B	57.63 M	N/A	42.37 M
Five Year Return	2.12 %	3.23 %	N/A	1.88 %	N/A	N/A	N/A
Beta	2.51	1.58	N/A	1.17	1.65	0.3	1.86
Number Of Employees	2.01 K	53 K	2	26 K	N/A	7	113
Shares Outstanding	77.15 M	324.24 M	12.4 M	496.26 M	N/A	32.91 M	8.37 M
Cash Flow From Operations	262.72 M	(408 M)	(1.32 M)	4.82 B	N/A	(17.3 M)	(65.07 M)
Annual Yield	0.0362 %	0.0434 %	N/A	0.0188 %	N/A	N/A	N/A
Total Debt	1.14 B	7.07 B	677.78 K	7.01 B	287.75 M	2.8 M	31.38 M
Return On Equity	0.2	-0.21	N/A	0.092	0.85	-9.16	-1.83
Z Score	1.62	2.35	2.29	8.78	-0.2	21.01	-6.56
Book Value Per Share	10.61 X	31.21 X	1.28 X	71.67 X	8.41 X	(0.35) X	0.49 X
Return On Asset	0.0849	-0.0454	N/A	0.0502	N/A	-1.07	-0.59
Number Of Shares Shorted	4.73 M	16.16 M	22.11 K	7.05 M	N/A	609.51 K	74.9 K
Current Liabilities	83.92 M	6.95 B	N/A	782.93 M	9.81 M	N/A	3.93 M
Total Asset	2.21 B	24.43 B	229.62 K	48.79 B	149.07 M	20.93 M	92.42 M
Debt To Equity	2.04 %	0.61 %	N/A	0.19 %	82.60 %	N/A	0.35 %
Last Dividend Paid	N/A	N/A	N/A	3.44	0.21	N/A	N/A
Short Ratio	5.57 X	2.31 X	1.19 X	2.06 X	N/A	3.40 X	0.44 X
Target Price	16.33	51.47	17.25	202.29	N/A	12.0	14.33
Shares Owned By Institutions	85.54 %	88.60 %	0.09 %	90.72 %	N/A	4.66 %	9.29 %
Market Capitalization	876.47 M	15.69 B	71.91 M	90.85 B	44.69 M	172.26 M	13.27 M
Price To Earning	37.14 X	31.52 X	N/A	49.43 X	21.82 X	N/A	(11.40) X
Price To Earnings To Growth	0.21 X	490.33 X	N/A	2.75 X	N/A	N/A	N/A
Price To Sales	0.53 X	1.34 X	N/A	7.38 X	N/A	N/A	N/A
Net Income	77.84 M	(1.71 B)	(1.74 M)	3.31 B	N/A	(40.08 M)	(77.53 M)
Earnings Per Share	1.91 X	(7.70) X	(0.53) X	6.55 X	0.07 X	(1.34) X	(8.93) X
Shares Owned By Insiders	3.25 %	0.21 %	84.66 %	0.38 %	N/A	7.95 %	25.53 %
Revenue	1.53 B	12.32 B	N/A	12.31 B	N/A	N/A	N/A
Working Capital	385.33 M	2.45 B	(1.06 M)	1.18 B	(27.84 M)	164 K	63.74 M
Cash And Equivalents	312.38 M	2.05 B	N/A	1.47 B	251.87 K	N/A	107.37 M
Cash Per Share	4.13 X	6.45 X	N/A	2.89 X	0.80 X	N/A	1.01 X
Gross Profit	454.96 M	5.87 B	N/A	7.8 B	N/A	N/A	N/A
Coefficient Of Variation	(1,849)	1062.89	(1,292)	3823.57	30299.71	(4,699)	(370.43)
Mean Deviation	1.67	1.65	3.36	1.07	3.62	3.54	3.47
Jensen Alpha	(0.15)	0.2054	(0.38)	0.0138	(0.018471)	(0.11)	(1.19)
Total Risk Alpha	(0.16)	0.1814	(0.44)	0.0071	(0.06)	(0.18)	(1.23)
Sortino Ratio	N/A	0.0768	N/A	0.0119	(0.00098154)	N/A	N/A
Downside Variance	N/A	7.03	N/A	1.7	21.09	N/A	N/A
Standard Deviation	2.28	2.38	4.66	1.38	4.92	4.94	4.29
Kurtosis	1.48	3.94	1.03	0.5876	0.4883	3.6	0.3763
Potential Upside	4.29	3.94	8.48	2.18	10.26	7.08	4.7
Treynor Ratio	(0.11)	0.2558	(0.43)	0.0226	0.0027	0.1283	(0.73)
Maximum Drawdown	12.65	15.13	22.93	5.46	18.71	28.7	21.26
Variance	5.18	5.69	21.76	1.92	24.17	24.39	18.4
Market Risk Adjusted Performance	(0.1)	0.2658	(0.42)	0.0326	0.0127	0.1383	(0.72)
Risk Adjusted Performance	(0.035458)	0.0799	(0.05)	0.0247	0.011	(0.008119)	(0.20)
Skewness	0.5241	(0.59)	0.1812	0.3557	0.7524	1.09	0.4109
Semi Deviation	N/A	2.34	N/A	1.27	3.77	N/A	N/A
Information Ratio	(0.06)	0.0854	(0.08)	0.0112	(0.00091671)	(0.02548)	(0.27)
Value At Risk	(3.43)	(3.52)	(7.64)	(2.05)	(7.41)	(8.15)	(7.05)
Expected Short fall	N/A	(1.64)	N/A	(1.14)	(5.45)	N/A	N/A
Downside Deviation	N/A	2.65	N/A	1.3	4.59	N/A	N/A
Semi Variance	N/A	5.48	N/A	1.61	14.2	N/A	N/A

Bristol-Myers Squibb Competition Performance Charts

Five steps to successful analysis of Bristol-Myers Squibb Competition

Bristol-Myers Squibb's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bristol-Myers Squibb in relation to its competition. Bristol-Myers Squibb's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Bristol-Myers Squibb in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bristol-Myers Squibb's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bristol-Myers Squibb, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bristol-Myers Squibb position

In addition to having Bristol-Myers Squibb in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals Funds Thematic Idea Now

Precious Metals Funds

Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 32 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.

View All Next

Launch

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Bristol-Myers Pink Sheet

If you are still planning to invest in Bristol-Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.

	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC